Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FENC Adherex Technologies	$7.84 -4.2%	$8.33	$3.96 ▼ $9.30	$226.86M	0.4	51,129 shs	54,838 shs
MNOV MediciNova	$1.43 +7.9%	$1.33	$1.12 ▼ $2.55	$64.99M	0.4	45,950 shs	68,485 shs
PRQR ProQR Therapeutics	$2.08 -1.0%	$2.05	$1.07 ▼ $4.62	$220.95M	0.43	209,588 shs	139,878 shs
TRDA Entrada Therapeutics	$5.80 -1.4%	$7.11	$5.62 ▼ $21.79	$223.16M	-0.11	142,142 shs	315,725 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FENC Adherex Technologies	-4.16%	-9.15%	-8.20%	+24.44%	+21.17%
MNOV MediciNova	+7.92%	-2.05%	+12.60%	-5.30%	+6.72%
PRQR ProQR Therapeutics	-0.95%	-6.73%	-2.35%	+4.52%	+7.77%
TRDA Entrada Therapeutics	-1.36%	-11.31%	-20.22%	-37.16%	-64.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FENC Adherex Technologies	1.8011 of 5 stars	3.6	1.0	0.6	3.3	0.0
MNOV MediciNova	2.678 of 5 stars	3.8	4.0	2.8	0.8	0.0
PRQR ProQR Therapeutics	2.1432 of 5 stars	3.6	3.0	3.2	0.0	0.0
TRDA Entrada Therapeutics	3.2087 of 5 stars	3.6	1.0	2.8	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FENC Adherex Technologies	3.25	Buy	$13.00	65.82% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	389.51% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	284.62% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	342.53% Upside

Current Analyst Ratings Breakdown

Latest MNOV, PRQR, TRDA, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FENC Adherex Technologies	$47.54M	4.57	$0.03 per share	253.28	($0.21) per share	-37.33
MNOV MediciNova	N/A	N/A	N/A	N/A	$1.07 per share	N/A
PRQR ProQR Therapeutics	$20.46M	10.70	N/A	N/A	$0.91 per share	2.29
TRDA Entrada Therapeutics	$172.22M	1.28	$1.56 per share	3.71	$11.46 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/6/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	7.16	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest MNOV, PRQR, TRDA, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	MNOV MediciNova	-$0.07	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FENC Adherex Technologies	-$0.06	N/A	N/A	N/A	$9.52 million	N/A
8/12/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	N/A	N/A	N/A	$8.17 million	N/A
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FENC Adherex Technologies	N/A	5.13	4.97
MNOV MediciNova	N/A	17.66	17.66
PRQR ProQR Therapeutics	N/A	4.10	4.10
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FENC Adherex Technologies	55.51%
MNOV MediciNova	9.90%
PRQR ProQR Therapeutics	32.65%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
FENC Adherex Technologies	11.76%
MNOV MediciNova	13.60%
PRQR ProQR Therapeutics	8.40%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FENC Adherex Technologies	10	27.73 million	24.47 million	Optionable
MNOV MediciNova	10	49.05 million	42.38 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.88 million	Optionable

MNOV, PRQR, TRDA, and FENC Headlines

Recent News About These Companies

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31 at 11:16 AM | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

July 11, 2025 | marketbeat.com

Ventures V. L.P. 5Am Sells 20,065 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - Should You Sell?

July 8, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025 | globenewswire.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.comP

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV, PRQR, TRDA, and FENC Company Descriptions

Adherex Technologies NASDAQ:FENC

$7.84 -0.34 (-4.16%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$7.86 +0.02 (+0.26%)

As of 08/1/2025 04:34 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

MediciNova NASDAQ:MNOV

$1.43 +0.11 (+7.92%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.38 -0.05 (-3.85%)

As of 08/1/2025 04:58 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

ProQR Therapeutics NASDAQ:PRQR

$2.08 -0.02 (-0.95%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.00 (+0.19%)

As of 08/1/2025 04:11 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Entrada Therapeutics NASDAQ:TRDA

$5.80 -0.08 (-1.36%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.80 0.00 (-0.09%)

As of 08/1/2025 04:10 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time